Prosight Capital is an SEC-registered investment adviser based in Dallas, TX that reports managing 2 hedge funds on Form ADV. It reports $1.0 billion in regulatory assets under management. Its private funds, of all types, hold $277.6 million in gross assets. Its disclosed U.S. stock holdings returned an estimated -1.1% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +26.7% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $1.0 billionForm ADV Item 5.F
- Gross assets of private funds
- $277.6 millionAll private fund types, Form ADV
- Hedge funds managed
- 22 private funds in total
- Employees
- 5Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 148791
- Latest Form ADV
- 03/30/2026Disciplinary disclosures: none reported
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +2.4% | +14.8% |
| Q1 2026 | -3.4% | -4.6% |
| Q4 2025 | +12.2% | +2.4% |
| Q3 2025 | +27.2% | +7.8% |
| Q2 2025 | +5.6% | +10.4% |
| Q1 2025 | -13.6% | -4.5% |
| Q4 2024 | -6.2% | +2.1% |
| Q3 2024 | +5.0% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
All 32 share positions ($515,482,740) reported by Prosight Management, LP on Form 13F for the quarter ended Sep 30, 2026, filed Nov 13, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Lakefront Biotherapeutics NV11.49%
- Shattuck Labs Inc10.12%
- Janux Therapeutics Inc9.87%
- Nektar Therapeutics9.22%
- Abivax SA7.24%
- Insmed Inc5.27%
- Boston Scientific Corp4.66%
- Irhythm Holdings Inc4.43%
- Alkermes PLC4.32%
- Privia Health Group Inc4.01%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Lakefront Biotherapeutics NV | $59,252,560 | 11.49% | 1,998,400 | -2.20% |
| Shattuck Labs Inc | $52,160,001 | 10.12% | 7,648,094 | +28.37% |
| Janux Therapeutics Inc | $50,858,496 | 9.87% | 2,943,200 | -22.64% |
| Nektar Therapeutics | $47,527,825 | 9.22% | 785,000 | -3.09% |
| Abivax SA | $37,310,142 | 7.24% | 376,794 | +250.85% |
| Insmed Inc | $27,175,364 | 5.27% | 238,088 | -36.61% |
| Boston Scientific Corp | $24,007,500 | 4.66% | 550,000 | -56.70% |
| Irhythm Holdings Inc | $22,843,387 | 4.43% | 200,980 | +21.44% |
| Alkermes PLC | $22,286,000 | 4.32% | 550,000 | +39.46% |
| Privia Health Group Inc | $20,669,617 | 4.01% | 1,049,752 | New |
| Mineralys Therapeutics Inc | $20,104,000 | 3.90% | 800,000 | +77.86% |
| Zymeworks Inc | $19,101,939 | 3.71% | 721,100 | +6.92% |
| Syndax Pharmaceuticals Inc | $15,276,542 | 2.96% | 812,582 | -32.28% |
| Kura Oncology Inc | $13,655,250 | 2.65% | 1,275,000 | -36.94% |
| Denali Therapeutics Inc | $11,382,969 | 2.21% | 550,700 | New |
| Praxis Precision Medicines I | $10,600,772 | 2.06% | 36,400 | New |
| Healthequity Inc | $10,243,314 | 1.99% | 115,796 | New |
| Bridgebio Pharma Inc | $9,870,000 | 1.91% | 150,000 | New |
| Alnylam Pharmaceuticals Inc | $9,129,380 | 1.77% | 37,000 | -62.28% |
| Humana Inc | $8,394,540 | 1.63% | 22,000 | New |
| Enovis Corporation | $4,885,983 | 0.95% | 267,432 | New |
| Onkure Therapeutics Inc | $3,612,178 | 0.70% | 1,325,570 | -9.73% |
| Quanterix Corp | $3,060,750 | 0.59% | 825,000 | New |
| Generate Biomedicines Inc | $2,174,235 | 0.42% | 144,756 | New |
| An2 Therapeutics Inc | $1,866,666 | 0.36% | 350,877 | -26.07% |
| Pliant Therapeutics Inc | $1,732,823 | 0.34% | 1,604,466 | +17.09% |
| Rocket Pharmaceuticals Inc | $1,564,913 | 0.30% | 595,024 | -15.00% |
| Rein Therapeutics Inc | $1,334,798 | 0.26% | 1,660,197 | +50.93% |
| Coya Therapeutics Inc | $1,150,296 | 0.22% | 229,600 | +35.06% |
| Corbus Pharmaceuticals Hldgs | $1,148,372 | 0.22% | 168,383 | -74.09% |
| Immuneering Corp | $614,250 | 0.12% | 150,000 | +306.93% |
| Adc Therapeutics SA | $487,878 | 0.09% | 399,900 | -94.89% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 9 new positions, 13 sold out, 10 increased, 13 reduced and 0 unchanged.
Number of positions (a count, not dollars)
- New positions9
- Increased10
- Unchanged0
- Reduced13
- Sold out13
New positions
| Stock | Value | Shares |
|---|---|---|
| Privia Health Group Inc | $20,669,617 | 1,049,752 |
| Denali Therapeutics Inc | $11,382,969 | 550,700 |
| Praxis Precision Medicines I | $10,600,772 | 36,400 |
| Healthequity Inc | $10,243,314 | 115,796 |
| Bridgebio Pharma Inc | $9,870,000 | 150,000 |
| Humana Inc | $8,394,540 | 22,000 |
| Enovis Corporation | $4,885,983 | 267,432 |
| Quanterix Corp | $3,060,750 | 825,000 |
| Generate Biomedicines Inc | $2,174,235 | 144,756 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Veeva SYS Inc | $18,847,314 | 106,200 |
| Crinetics Pharmaceuticals In | $14,020,002 | 374,666 |
| Icu Med Inc | $7,476,600 | 51,000 |
| Intuitive Surgical Inc | $6,760,560 | 17,000 |
| Procept Biorobotics Corp | $6,057,514 | 268,269 |
| Genedx Holdings Corp | $5,869,575 | 85,500 |
| Option Care Health Inc | $5,676,915 | 270,716 |
| Emergent Biosolutions Inc | $3,854,398 | 459,952 |
| Pfizer Inc | $3,259,613 | 135,366 |
| Orthopediatrics Corp | $3,012,975 | 157,500 |
| Tectonic Therapeutic Inc | $1,365,753 | 39,731 |
| Meiragtx Hldgs PLC | $1,215,900 | 90,000 |
| Everforth Inc | $1,206,225 | 67,500 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Abivax SA | +269,400 | +250.85% | $37,310,142 | 376,794 |
| Shattuck Labs Inc | +1,690,217 | +28.37% | $52,160,001 | 7,648,094 |
| Mineralys Therapeutics Inc | +350,205 | +77.86% | $20,104,000 | 800,000 |
| Alkermes PLC | +155,611 | +39.46% | $22,286,000 | 550,000 |
| Irhythm Holdings Inc | +35,480 | +21.44% | $22,843,387 | 200,980 |
| Zymeworks Inc | +46,666 | +6.92% | $19,101,939 | 721,100 |
| Immuneering Corp | +113,139 | +306.93% | $614,250 | 150,000 |
| Rein Therapeutics Inc | +560,197 | +50.93% | $1,334,798 | 1,660,197 |
| Coya Therapeutics Inc | +59,600 | +35.06% | $1,150,296 | 229,600 |
| Pliant Therapeutics Inc | +234,233 | +17.09% | $1,732,823 | 1,604,466 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Boston Scientific Corp | -720,273 | -56.70% | $24,007,500 | 550,000 |
| Insmed Inc | -137,521 | -36.61% | $27,175,364 | 238,088 |
| Alnylam Pharmaceuticals Inc | -61,080 | -62.28% | $9,129,380 | 37,000 |
| Janux Therapeutics Inc | -861,281 | -22.64% | $50,858,496 | 2,943,200 |
| Adc Therapeutics SA | -7,424,849 | -94.89% | $487,878 | 399,900 |
| Kura Oncology Inc | -746,964 | -36.94% | $13,655,250 | 1,275,000 |
| Syndax Pharmaceuticals Inc | -387,418 | -32.28% | $15,276,542 | 812,582 |
| Corbus Pharmaceuticals Hldgs | -481,617 | -74.09% | $1,148,372 | 168,383 |
| Nektar Therapeutics | -25,000 | -3.09% | $47,527,825 | 785,000 |
| Lakefront Biotherapeutics NV | -44,944 | -2.20% | $59,252,560 | 1,998,400 |
| An2 Therapeutics Inc | -123,761 | -26.07% | $1,866,666 | 350,877 |
| Onkure Therapeutics Inc | -142,918 | -9.73% | $3,612,178 | 1,325,570 |
| Rocket Pharmaceuticals Inc | -104,976 | -15.00% | $1,564,913 | 595,024 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. | 13G amendment | 5.14% | 3,144,200 | Nov 13, 2026 | SEC.gov ↗ |
| ADC Therapeutics SA | 13G amendment | 0.31% | 399,900 | Nov 13, 2026 | SEC.gov ↗ |
| OnKure Therapeutics, Inc. | 13G amendment | 2.4% | 978,992 | Aug 10, 2026 | SEC.gov ↗ |
| MeiraGTx Holdings plc | 13G amendment | 4% | 3,209,788 | Feb 13, 2026 | SEC.gov ↗ |
| Mural Oncology plc | 13G amendment | 0% | 0 | Nov 13, 2025 | SEC.gov ↗ |
| Shattuck Labs, Inc. | 13G amendment | 9.9% | 6,543,240 | Nov 13, 2025 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 13, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (2)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (2)
As reported in the adviser's Form ADV filed Mar 27, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures